STOCK TITAN

Verastem (VSTM) Stock Price, News & Analysis

VSTM NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
55 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+19.7% close of October 15, 2026
1-year change
-19% closing prices, November 17, 2025 to November 17, 2026
1-month change
-14.3% closing prices, October 16, 2026 to November 17, 2026

Company Description

Verastem, Inc. (Verastem Oncology, Nasdaq: VSTM) is a late-stage development biopharmaceutical company focused on developing and commercializing new medicines for patients diagnosed with RAS/MAPK pathway-driven cancers. According to multiple company disclosures, Verastem Oncology is committed to advancing novel small molecule drugs that inhibit signaling pathways in cancer that promote tumor cell survival and growth, with particular emphasis on RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition.

Verastem trades on The Nasdaq Capital Market under the ticker symbol VSTM, as noted in its SEC filings. The company describes itself as a late-stage development biopharmaceutical organization, reflecting its combination of an approved commercial product and an active pipeline of clinical-stage candidates targeting genetically and pathway-defined solid tumors.

Core commercial product: AVMAPKI FAKZYNJA CO-PACK

A central element of Verastem’s business is the U.S. commercialization of AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets). Company communications state that Verastem markets AVMAPKI FAKZYNJA CO-PACK in the United States for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication was granted accelerated approval by the U.S. Food and Drug Administration (FDA) based on tumor response rate and duration of response, with continued approval potentially contingent on verification and description of clinical benefit in a confirmatory trial.

AVMAPKI FAKZYNJA CO-PACK combines two targeted agents:

  • AVMAPKI (avutometinib), described as an oral RAF/MEK “clamp” that inhibits MEK kinase activity and blocks compensatory reactivation of MEK by upstream RAF within the RAS/RAF/MEK/ERK (MAPK) pathway.
  • FAKZYNJA (defactinib), a focal adhesion kinase (FAK) inhibitor intended to counteract FAK activation, which is characterized as a key mediator of drug resistance.

According to the company, the combination of avutometinib and defactinib is designed to provide a more complete blockade of signaling that drives growth and drug resistance in RAS/MAPK pathway-dependent tumors. AVMAPKI FAKZYNJA CO-PACK is not approved by the FDA or other regulators for uses beyond the specified LGSOC indication, and neither avutometinib nor defactinib is approved on a stand-alone basis for any indication.

Pipeline focus: RAS/MAPK pathway and KRAS G12D

Beyond its commercial product, Verastem’s pipeline is focused on novel small molecule drugs targeting critical signaling pathways in cancer. Company descriptions highlight three main mechanistic areas:

  • RAF/MEK inhibition through avutometinib, aimed at blocking key kinases in the MAPK pathway.
  • FAK inhibition through defactinib, intended to address mechanisms of drug resistance.
  • KRAS G12D inhibition, centered on the oral small molecule VS-7375, described as a potential best-in-class KRAS G12D (ON/OFF) inhibitor.

VS-7375 is identified as the lead program from Verastem Oncology’s discovery and development collaboration with GenFleet Therapeutics. SEC filings and press releases state that Verastem’s U.S. Investigational New Drug (IND) application for VS-7375 was cleared and that the company initiated a Phase 1/2a clinical trial in patients with advanced KRAS G12D mutant solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer. Verastem holds development and commercialization rights to VS-7375 outside GenFleet’s specified markets.

Key clinical development programs

Verastem describes several ongoing or planned clinical trials built around its targeted agents:

  • RAMP 301: An international Phase 3 confirmatory trial evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy in recurrent LGSOC with and without a KRAS mutation. This study is intended to serve as a confirmatory trial for the accelerated approval indication and may support potential expansion of the indication.
  • RAMP 205: A trial assessing avutometinib plus defactinib with standard-of-care chemotherapy as a potential first-line treatment for patients with advanced pancreatic cancer.
  • RAMP 203: A Phase 1/2 trial, conducted in collaboration with Amgen, evaluating avutometinib and LUMAKRAS (sotorasib) as a doublet, and avutometinib plus defactinib with LUMAKRAS as a triplet, in patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC). Verastem has reported interim data and later announced its decision to discontinue RAMP 203 in order to focus resources on VS-7375 and other priority programs.
  • VS-7375-101 Phase 1/2a study: A dose-escalation and expansion trial in the U.S. evaluating VS-7375 as monotherapy and in combination with other standard-of-care treatments, including cetuximab, in advanced KRAS G12D mutant solid tumors such as pancreatic, colorectal, and NSCLC.

In addition, Verastem has cited updated data from GenFleet’s Phase 1/2 studies of VS-7375 (GFH375) in China, including results in advanced pancreatic ductal adenocarcinoma and NSCLC, to support further development planning.

Business model and stage

Company statements describe Verastem Oncology as both a commercial-stage and late-stage development biopharmaceutical company. The business model centers on:

  • Commercialization of AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent LGSOC.
  • Clinical development of avutometinib and defactinib combinations in multiple solid tumors, including ovarian and pancreatic cancers and NSCLC.
  • Early- to mid-stage development of VS-7375 as an oral KRAS G12D inhibitor in collaboration with GenFleet.

Verastem has also used public equity offerings and pre-funded warrants, as detailed in its Form 8-K filings, to raise capital for commercial activities related to AVMAPKI FAKZYNJA CO-PACK and for continued research and development of its product candidates, including VS-7375.

Regulatory and safety considerations

Because AVMAPKI FAKZYNJA CO-PACK is an FDA-approved therapy, Verastem’s public materials include detailed Important Safety Information. These disclosures highlight key warnings and precautions, such as:

  • Ocular toxicities, including visual impairment and vitreoretinal disorders, with recommendations for baseline and periodic ophthalmic evaluations and guidance on dose interruption or discontinuation for severe events.
  • Serious skin toxicities, including photosensitivity and severe cutaneous adverse reactions, with instructions to monitor and adjust dosing based on severity and duration.
  • Hepatotoxicity, with recommendations for regular liver function monitoring and dose modification as needed.
  • Rhabdomyolysis, with guidance on monitoring creatine phosphokinase and managing suspected cases.
  • Embryo-fetal toxicity, including advice that the therapy can cause fetal harm and that effective contraception should be used.

The company also lists common adverse reactions (including laboratory abnormalities) observed at a frequency of 25% or greater, and provides information on drug interactions, such as avoiding strong or moderate CYP3A4 inhibitors or inducers, warfarin, and certain gastric acid-reducing agents when co-administered with AVMAPKI FAKZYNJA CO-PACK.

Sector and classification

Based on the provided industry classification, Verastem, Inc. operates within Pharmaceutical Preparation Manufacturing in the broader Manufacturing sector. Its activities, as described in company and regulatory documents, are characteristic of a biopharmaceutical issuer with a focus on oncology drug development, targeted small molecules, and regulatory approval pathways such as accelerated approval with confirmatory requirements.

Status and trading

Recent SEC filings, including multiple Forms 8-K, identify Verastem, Inc. as a registrant with common stock listed on The Nasdaq Capital Market under the symbol VSTM. These filings do not indicate delisting, deregistration, or bankruptcy events. Instead, they describe ongoing capital markets activity, clinical updates, and corporate communications, consistent with an actively operating public biopharmaceutical company.

Stock Performance

$7.35
-0.81%
-0.06
Pre-marketLast updated: at
-19%
Performance 1 year
$926.2M

Verastem (VSTM) closed at $7.41 on November 17, 2026. Over the past 12 months, the price has lost 19.0%.

See what a $1,000 investment in VSTM would be worth today

Average down calculator for VSTM

VSTM Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Verastem has 10 recent news articles, with the latest published on . Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, earnings date, offering. View all VSTM news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
48,041
Shares Sold
4
Transactions
Most Recent Transaction
Paterson Dan (President and CEO) sold 1,299 shares @ $9.60 on November 3, 2026

Insider selling at Verastem over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Verastem generated $30.9M in revenue in FY2025, operating income reached -$170.1M, and net income was -$209.5M. Diluted earnings per share stood at -$3.02. The company generated -$137.5M in operating cash flow. The current ratio was 3.09, measuring current assets divided by current liabilities.

$30.9M
Revenue (FY2025)
-$209.5M
Net Income (FY2025)
-$137.5M
Operating Cash Flow

Upcoming Events

DEC
05
December 5, 2026 Clinical

Late-breaking oral presentation

Late-breaking oral presentation of updated VS-7375 TARGET-D-101 lung cancer data at IASLC/ASCO on Dec 5, 2026; investor-relevant
DEC
05
December 5, 2026 Clinical

Conference poster presentation

Poster presentation covering ongoing Phase 2 TARGET-D 202 lung cancer trial at IASLC/ASCO; supports future regulatory filing
DEC
31
December 31, 2026 Clinical

Phase 3 trial start

Planned opening of Phase 3 first-line metastatic pancreatic cancer trial by year-end 2026 after FDA-agreed design; US sites, enrollment planned.
YEAR
2026
2026 Clinical

Phase 2 enrollment completion

Verastem aims to complete enrollment of Phase 2 TARGET-D trials by year-end 2026; milestone for regulatory path.
JAN
01
January 1, 2027 Corporate

CEO appointment

Michael P. Bailey to become President & CEO effective Jan 1, 2027; Daniel Paterson will retire and remain as director/advisor.
H1
2027
H1 2027 Clinical

Phase 3 trial start

Planned start of VS-7375 Phase 3 trials in 1H 2027, per company guidance; initiation window January–June 2027.
FEB
07
February 7, 2027 Regulatory

FDA decision FAKZYNJA

Regulatory decision due on AVMAPKI FAKZYNJA co-pack blister pack on 2027-02-07; potential commercial impact and labeling/approval outcome.
APR
02
April 2, 2027 Corporate

25% RSUs vest

25% of 141,000 RSUs granted 2026-04-02 to 11 new employees vests.
APR
02
April 2, 2027 - April 2, 2030 Corporate

Remaining RSUs vest quarterly

Remaining 75% vests quarterly over the three years following the one-year anniversary.
YEAR
2027
2027 Clinical

RAMP 301 topline readout

Topline results for RAMP 301 pivotal trial expected mid-2027 per company disclosure.
YEAR
2027
2027 Clinical

Topline trial results

RAMP 301 Phase 3 topline primary-endpoint results expected; company remains blinded

Verastem has 11 upcoming scheduled events. The next event, "Late-breaking oral presentation", is scheduled for December 5, 2026 (in 17 days). Investors can track these dates to stay informed about potential catalysts that may affect the VSTM stock price.

Short Interest History

Last 12 Months

Short interest in Verastem (VSTM) currently stands at 19.7 million shares, up 14.3% from the previous reporting period, representing 16.3% of the float.

Days to Cover History

Last 12 Months

Days to cover for Verastem (VSTM) currently stands at 5.2 days, up 107.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 2.5 to 13.5 days.

VSTM Company Profile & Sector Positioning

Verastem (VSTM) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing VSTM often look at related companies in the same sector, including MoonLake Immunotherapeutics (MLTX), Jade Biosciences, Inc. (JBIO), Corvus Pharmaceuticals, Inc. (CRVS), Savara Inc. (SVRA), and Immatics N.V. (IMTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate VSTM's relative position within its industry.

Frequently Asked Questions

The current stock price of Verastem (VSTM) is $7.35 in pre-market trading as of November 18, 2026.

The market cap of Verastem (VSTM) is approximately $926.2M. Learn more about what market capitalization means .

The FY2025 revenue of Verastem (VSTM) is $30.9M, from its most recent completed fiscal year.

The FY2025 net income of Verastem (VSTM) is -$209.5M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Verastem (VSTM) is -$3.02 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Verastem (VSTM) is -$137.5M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Verastem (VSTM), current assets divided by current liabilities, was 3.09 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Verastem (VSTM) is -$170.1M for FY2025, its most recent completed fiscal year. Learn about operating income.

Verastem, Inc., also known as Verastem Oncology, is a late-stage development biopharmaceutical company focused on developing and commercializing new medicines for patients with RAS/MAPK pathway-driven cancers. It emphasizes small molecule drugs that inhibit key signaling pathways such as RAF/MEK, FAK, and KRAS G12D.

Verastem’s main approved product is AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib capsules and defactinib tablets. It is indicated in the U.S. for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy, under FDA accelerated approval.

According to Verastem, AVMAPKI (avutometinib) inhibits MEK kinase activity and blocks compensatory reactivation of MEK by RAF in the RAS/RAF/MEK/ERK (MAPK) pathway, while FAKZYNJA (defactinib) inhibits focal adhesion kinase (FAK), a mediator of drug resistance. The combination is designed to more fully block signaling that drives tumor growth and resistance in RAS/MAPK pathway-dependent cancers.

Verastem’s pipeline focuses on novel small molecule drugs targeting critical signaling pathways in cancer, particularly RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. Key programs include the avutometinib and defactinib combinations in recurrent low-grade serous ovarian cancer and pancreatic cancer, and the KRAS G12D inhibitor VS-7375 in advanced solid tumors.

VS-7375 is described as a potential best-in-class, potent, and selective oral KRAS G12D (ON/OFF) inhibitor. It is being evaluated in a Phase 1/2a trial in patients with advanced KRAS G12D mutant solid tumors, including pancreatic ductal adenocarcinoma, non-small cell lung cancer, and other solid tumors, both as monotherapy and in combination with other treatments such as cetuximab.

Verastem highlights several key trials: RAMP 301, a Phase 3 confirmatory trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer; RAMP 205, evaluating the same combination with chemotherapy in first-line metastatic pancreatic cancer; RAMP 203, a Phase 1/2 study with Amgen evaluating combinations including LUMAKRAS in KRAS G12C-mutated NSCLC; and VS-7375-101, a Phase 1/2a trial of VS-7375 in KRAS G12D mutant solid tumors.

Verastem’s common stock is registered on The Nasdaq Capital Market under the ticker symbol VSTM, as disclosed in the company’s Form 8-K filings.

Verastem describes itself as a late-stage development biopharmaceutical company. It has an FDA-approved oncology product on the market in the U.S. and is running late-stage trials such as the Phase 3 RAMP 301 study, alongside earlier-stage development of pipeline candidates like the KRAS G12D inhibitor VS-7375.

Company safety information notes that AVMAPKI FAKZYNJA CO-PACK can cause ocular toxicities, serious skin toxicities, hepatotoxicity, rhabdomyolysis, and embryo-fetal toxicity, among other adverse reactions. Verastem recommends specific monitoring and dose modifications based on the severity and persistence of these events.

No. Verastem states that AVMAPKI FAKZYNJA CO-PACK is indicated for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Avutometinib and defactinib, alone or in other combinations, are not approved by the FDA or other regulatory authorities for additional indications.

Verastem has conducted underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement on Form S-3. The company has stated that net proceeds are used to fund commercial activities for AVMAPKI FAKZYNJA CO-PACK, support clinical research and development of product candidates such as VS-7375, and for working capital and general corporate purposes.